Publikationen

KORNMANN

Govoni M, Bassi M, Vezzoli S, et al. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. Respir Res. 2020;21(1):72. Published 2020 Mar 20. doi:10.1186/s12931-020-1329-y

Kornmann O, Mucsi J, Kolosa N, et al. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings. Respir Med. 2020;161:105809. doi:10.1016/j.rmed.2019.105809

Singh D, Beeh KM, Colgan B, et al. Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD. Respir Res. 2019;20(1):180. Published 2019 Aug 9. doi:10.1186/s12931-019-1142-7

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN. Indacaterol Acetate/Mometasone Furoate Provides Sustained Improvements in Lung Function Compared With Salmeterol Xinafoate/Fluticasone Propionate in Patients With Moderate-To-Very-Severe COPD: Results From a Phase II Randomized, Double-Blind 12-week Study. Int J Chron Obstruct Pulmon Dis , 13, 3923-3936, 2018

Khindri S, Cahn A, Begg M, et al. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma. J Pharmacol Exp Ther. 2018;367(3):405–413. doi:10.1124/jpet.118.249516

Pouliquen IJ, Kornmann O, Barton SV, Price JA, Ortega HG. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015;53(12):1015–1027. doi:10.5414/CP202446

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, and Renz H. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015 May 21;372(21):1987-95

Kerstjens HA, Deslée G, Dahl R, et al. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D. Pulm Pharmacol Ther. 2015;32:101–108. doi:10.1016/j.pupt.2015.02.008

Kornmann O, Watz H, Fuhr R, Krug N, Erpenbeck VJ, Kaiser G. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table. Pulm Pharmacol Ther. 2014;28(2):149–153. doi:10.1016/j.pupt.2014.03.003

Bateman ED, Kornmann O, Ambery C, Norris V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther. 2013;26(5):581–587. doi:10.1016/j.pupt.2013.03.015

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med. 2013;107(2):223–232. doi:10.1016/j.rmed.2012.10.022

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:477–492. doi:10.2147/COPD.S23816

Bateman ED, Kornmann O, Schmidt P, Pivovarova A, Engel M, Fabbri LM. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol. 2011 Aug;128(2):315-22.doi: 10.1016/j.jaci.2011.06.004.

Taube C, Rydzy L, Eich A, Korn S, Kornmann O, Sebastian M, Jörres RA, Buhl R.Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. Respir Med. 2011 Feb;105(2):316-21. doi:10.1016/j.rmed.2010.11.017.

Korn S, Telke I, Kornmann O, Buhl R. Measurement of exhaled nitric oxide: comparison of different analysers. Respirology. 2010 Nov;15(8):1203-8. doi:10.1111/j.1440-1843.2010.01847.x.

Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011 Feb;37(2):273-9. doi:10.1183/09031936.00045810.

Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009 Nov;103(11):1725-31. doi: 10.1016/j.rmed.2009.05.002.

Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC.

Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, Stenglein S, Seyfried S, Wahn U; DUAL study group. Combination of omalizumab and specificimmunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009 Feb;39(2):271-9. doi: 10.1111/j.1365-2222.2008.03121.x.

Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008 Jul;102(7):1033-44. doi: 10.1016/j.rmed.2008.02.001.

Grönke L, Beeh KM, Cameron R, Kornmann O, Beier J, Shaw M, Holz O, Buhl R, Magnussen H, Jörres RA. Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17.

Korn S, Beier J, Heilmann C, Kornmann O, Buhl R, Michael Beeh K. Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions. Respir Med. 2005 Dec;99(12):1595-9

Beier J, Beeh KM, Kornmann O, Buhl R. Induced sputum methodology: Validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. J Lab Clin Med. 2004 Jul;144(1):38-44.

Beeh KM, Kornmann O, Beier J, Ksoll M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respir Med. 2004 Jul;98(7):591-7.

Beier J, Beeh KM, Kornmann O, Buhl R. Stability of glutathione in induced sputum: impact of freezing. Respiration. 2003 Sep-Oct;70(5):523-7.

Beier J, Beeh KM, Kornmann O, Morankic E, Ritter N, Buhl R. Dissimilarity between seasonal changes in airway responsiveness to adenosine-5'-monophosphate and methacholine in patients with grass pollen allergic rhinitis: relation to induced sputum. Int Arch Allergy Immunol. 2003 Sep;132(1):76-81.

Beier J, Beeh KM, Kornmann O, Buhl R. Sputum induction leads to a decrease of exhaled nitric oxide unrelated to airflow. Eur Respir J. 2003 Aug;22(2):354-7.

Beeh KM, Beier J, Kornmann O, Buhl R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2003 Jun;20(2):138-43.

Beeh KM, Beier J, Kornmann O, Buhl R. Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. Respir Med. 2003 Jun;97(6):634-9.

Beeh KM, Beier J, Ernst M, Kornmann O, Buhl R. Platinum-based, leukocyte-depleting chemotherapy does not alter induced sputum markers of neutrophilic inflammation in COPD patients with unresectable non-small cell lung cancer. Respiration. 2003 Mar-Apr;70(2):166-71.

Beeh KM, Beier J, Kornmann O, Meier C, Taeumer T, Buhl R. A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clin Exp Allergy. 2003 Apr;33(4):475-82.

Beeh KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ. Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003 Apr;123(4):1240-7.

Beeh KM, Beier J, Kornmann O, Mander A, Buhl R. Long-term repeatability of induced sputum cells and inflammatory markers in stable, moderately severe COPD. Chest. 2003 Mar;123(3):778-83.

Kornmann O, Beeh KM, Beier J, Geis UP, Ksoll M, Buhl R; Global Initiative for Obstructive Lung Disease. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration. 2003 Jan-Feb;70(1):67-75.

Beeh KM, Beier J, Haas IC, Kornmann O, Micke P, Buhl R. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2002 Jun;19(6):1119-23.

Beeh KM, Beier J, Kornmann O, Wiewrodt R, Buhl R; SAS 40011-Studiengruppe. [Efficacy and safety of salmeterol (50 microgram) and fluticasone (250 microgram) in a single inhaler device (diskus) in patients with mild to moderate asthma].Pneumologie. 2002 Feb;56(2):91-7. German.

Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant. 2001 Nov;20(11):1144-51.

Beeh KM, Kornmann O, Lill J, Buhl R. Induced sputum cell profiles in lung transplant recipients with or without chronic rejection: correlation with lung function. Thorax. 2001 Jul;56(7):557-60.

Beeh KM, Micke P, Kornmann O, Buhl R. [Correlation of plasma glutathione and total IgE level: evidence for a regulatory role of antipxodants in vivo]. Pneumologie. 2000 Dec;54(12):569-71. German.